Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriales infection: are they the same in neutropenic and non-neutropenic patients?

  • Filippo LagiEmail author
  • Giampaolo Corti

Febrile neutropenia (FN) is one of the most frequent and serious complications of chemotherapy for cancer. Neutropenia is defined by an abnormal reduction of neutrophils usually within 7–12 days after chemotherapy. According to the European Society for Medical Oncology (ESMO), FN is defined as “an oral temperature of > 38.3 °C or two consecutive readings of > 38.0 °C for 2 h and an absolute neutrophil count (ANC) of < 0.5 × 109/L, or expected to fall below 0.5 × 109/L” [1]. Neutropenic patients may be less capable of fighting infections due to the reduced levels of neutrophils in circulation.  In patients with FN, the prognosis is worst in case of proven bacteremia, with mortality rates of 18% in Gram-negative and 5% in Gram-positive bacteremia [2]. During the last decade, the global increase in the prevalence of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriales has also affected immunocompromised patients [3]. ESBLs can hydrolyze many beta-lactams except for...


Compliance with ethical standards

Conflict of interest

The authors state that they have no conflicts of interest.

Statements on human and animal rights

The article does not contain any studies with human participants or animals performed by the author.

Informed consent



  1. 1.
    Klastersky J, de Naurois J, Rolston K et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111–v118. CrossRefGoogle Scholar
  2. 2.
    Klastersky J, Ameye L, Maertens J et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30:S51–S59. CrossRefGoogle Scholar
  3. 3.
    Trecarichi EM, Tumbarello M, Spanu T et al (2009) Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307. CrossRefGoogle Scholar
  4. 4.
    Rottier WC, Ammerlaan HSM, Bonten MJM (2012) Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67:1311–1320. CrossRefGoogle Scholar
  5. 5.
    Hayden MK, Won SY (2018) Carbapenem-sparing therapy for extended-spectrum β-lactamase-producing E. coli and Klebsiella pneumoniae bloodstream infection: the search continues. JAMA J Am Med Assoc 320:979–981. CrossRefGoogle Scholar
  6. 6.
    Harris PNA, Tambyah PA, Lye DC et al (2018) Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance. JAMA J Am Med Assoc 320:984–994. CrossRefGoogle Scholar
  7. 7.
    Barlam TF, Cosgrove SE, Abbo LM et al (2016) Executive summary: Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis 62:1197–1202. CrossRefGoogle Scholar
  8. 8.
    Fawcett NJ (2018) Reducing carbapenem prescribing in high-use settings: it is possible, and it is good to talk. Intern Emerg Med 13:1179–1180. CrossRefGoogle Scholar
  9. 9.
    Goodman KE, Lessler J, Cosgrove SE et al (2016) A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase-producing organism. Clin Infect Dis 63:896–903. CrossRefGoogle Scholar
  10. 10.
    Ortega M, Marco F, Soriano A et al (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63:568–574. CrossRefGoogle Scholar
  11. 11.
    Ben-Chetrit E, El Dahim MA, Bar-Meir M et al (2018) Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia. Int J Antimicrob Agents. Google Scholar
  12. 12.
    Kim Y-J, Jung SM, Kang J et al (2019) Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. Intern Emerg Med. Google Scholar
  13. 13.
    Castanheira M, Farrell SE, Krause KM et al (2014) Contemporary diversity of β-lactamases among enterobacteriaceae in the nine U.S. census regions and ceftazidime–avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58:833–838. CrossRefGoogle Scholar
  14. 14.
    Morrissey I, Hackel M, Badal R et al (2013) A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals 6:1335–1346. CrossRefGoogle Scholar
  15. 15.
    Pitout JD, Laupland KB (2009) Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159–166. CrossRefGoogle Scholar
  16. 16.
    Mathers AJ, Peirano G, Pitout JDD (2015) The role of epidemic resistance plasmids and international high- risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev 28:565–591. CrossRefGoogle Scholar
  17. 17.
    Scheuerman O, Schechner V, Carmeli Y et al (2018) Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 39:660–667. CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  2. 2.Infectious and Tropical Diseases UnitCareggi University HospitalFlorenceItaly

Personalised recommendations